Adaptimmune Announces Pricing of Initial Public Offering
(Thomson Reuters ONE) -
OXFORD, United Kingdom and PHILADELPHIA, May 6, 2015 (GLOBE NEWSWIRE) --
Adaptimmune Therapeutics plc (Nasdaq:ADAP) today announced the pricing of its
initial public offering of 11,250,000 American Depositary Shares (ADSs) at a
price to the public of $17.00 per ADS. In addition, the underwriters have been
granted a 30-day option to purchase up to an additional 1,687,500 ADSs. The ADSs
are expected to begin trading on the NASDAQ Global Select Market under the
symbol "ADAP" on May 6, 2015. The offering is expected to close on May
11, 2015, subject to customary closing conditions. Adaptimmune estimates net
proceeds from the offering will be approximately $175.7 million.
BofA Merrill Lynch, Cowen and Company and Leerink Partners LLC are acting as
joint book-running managers and Guggenheim Securities is acting as lead manager
for the offering.
A registration statement relating to these securities was declared effective by
the Securities and Exchange Commission (SEC) on May 5, 2015.
This offering is made only by means of a written prospectus forming part of the
effective registration statement. A copy of the final prospectus related to the
offering will be filed with the SEC and may be obtained at no cost, when
available, by visiting EDGAR on the SEC's website (www.sec.gov), or from: BofA
Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or
by email at dg.prospectus_requests(at)baml.com; Cowen and Company, LLC, c/o
Broadridge Financial Services, Attention: Prospectus Department, 1155 Long
Island Avenue, Edgewood, NY 11717, Telephone: 631-274-2806, Fax: 631-254-7140;
or Leerink Partners LLC, Attention: Syndicate Department, One Federal Street,
37th Floor, Boston, MA 02110, by email at syndicate(at)leerink.com, or by phone at
(800) 808-7525 ext. 6142.
This press release shall not constitute an offer to sell or the solicitation of
an offer to buy, nor shall there be any sale of, these securities in any state
or jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of such state
or jurisdiction.
This communication is being directed only at (i) persons who are outside the
United Kingdom or (ii) persons who have professional experience in matters
relating to investments who fall within Article 19(5) ("Investment
professionals") of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the "Order") or (iii) certain high value persons and
entities who fall within Article 49(2)(a) to (d) ("High net worth companies,
unincorporated associations etc") of the Order; or (iv) any other person to whom
it may lawfully be communicated (all such persons in (i) to (iv) together being
referred to as "relevant persons"). The ADSs are only available to, and any
invitation, offer or agreement to subscribe, purchase or otherwise acquire such
ADSs will be engaged in only with, relevant persons. Any person who is not a
relevant person should not act or rely on this document or any of its contents.
About Adaptimmune
Adaptimmune is a clinical stage biopharmaceutical company focused on novel
cancer immunotherapy products based on its T-cell receptor platform. Established
in 2008, the company aims to utilize the body's own machinery - the T cell - to
target and destroy cancer cells by using engineered, increased affinity T cell
receptors (TCRs) as a means of strengthening natural patient T cell responses.
Adaptimmune's lead program is an affinity enhanced TCR therapeutic targeting the
NY-ESO cancer antigen. Its NY-ESO TCR therapeutic candidate has demonstrated
signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in
hematologic cancer types. In June 2014, Adaptimmune announced that it had
entered into a strategic collaboration and licensing agreement with
GlaxoSmithKline for the development and commercialization of the NY-ESO TCR
program. The Company currently has over 100 employees.
CONTACT: Adaptimmune Contact
Margaret Henry
Head of PR
T: +44 (0)1235 430036
Mob: +44 (0)7710 304249
E: margaret.henry(at)adaptimmune.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Adaptimmune LLC via GlobeNewswire
[HUG#1919115]
Unternehmensinformation / Kurzprofil:
Datum: 06.05.2015 - 13:00 Uhr
Sprache: Deutsch
News-ID 391407
Anzahl Zeichen: 5136
contact information:
Town:
Philadelphia
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 187 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Adaptimmune Announces Pricing of Initial Public Offering"
steht unter der journalistisch-redaktionellen Verantwortung von
Adaptimmune LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
